Edu Hortelano retweeted
100+ AI Tools to replace your tedious work:
1. Research
- ChatGPT
- YouChat
- Abacus
- Perplexity
- Copilot
- Gemini
2. Image
- Higgsfield AI Soul
- GPT-4o
- Midjourney
- Grok
3. Productivity
- Gamma
- Grok 3
- Perplexity AI
- Gemini 2.5 Flash
4. Writing
- Jasper
- Jenny AI
- Textblaze
- Quillbot
5. Video
- Klap
- Kling
- InVideo
- HeyGen
- Runway
6. Meeting
- Tldv
- Otter
- Noty AI
- Fireflies
7. SEO
- VidIQ
- Seona AI
- BlogSEO
- Keywrds ai
- Outrank AI
8. Presentation
- Decktopus
- Slides AI
- Gamma AI
- Designs AI
- Beautiful AI
9. Design
- Canva
- Flair AI
- Designify
- Clipdrop
- Autodraw
- Magician design
10. Audio
- Lovo ai
- Eleven labs
- Songburst AI
- Adobe Podcast
11. Marketing
- Pencil
- Ai-Ads
- AdCopy
- Simplified
- AdCreative
12. Startup
- Tome
- Ideas AI
- Namelix
- Pitchgrade
- Validator AI
13. Social media management
- Tapilo
- Typefully
- Hypefury
- TweetHunter
Follow @sripathiteja4 for more.
Edu Hortelano retweeted
CHAARTED 10-Year Analysis
PSA nadir <0.2 at 6 months predicts better long-term survival in metastatic hormone-sensitive prostate cancer (mHSPC), independent of treatment arm!
Could PSA nadir be a future de-escalation marker? @ChrisSweens1
#ProstateCancer #Oncology #CancerResearch #PrecisionMedicine @asco @oncoalert @MikeSerzanMD @drenriquegrande @crisbergerot @reginabarcar @DRBakaloudiMD @abvilima @ReneeSaliby @yekeduz_emre @neerajaiims @DrChoueiri @montypal @PGrivasMDPhD @CParkMD @OncLive @amerseburger
Edu Hortelano retweeted
Another great metastatic prostate cancer "landscape" figure from @aaparicioMD during her aggressive variant prostate cancer talk at #ESMO25
Approved, and "likely to be approved"/new data (bottom), treatment options
@urotoday
Drug Approvals in 🇺🇸 for Prostate Cancer (2010-2025)
Go ahead and bookmark this beauty from @PBarataMD
@urotoday #ESMO25
ASCO 2025 Plenary Highlights: Key Practice-Changing Data Across TOP 5 ATOMIC, MATTERHORN, SERENA-6, VERIFY, and NIVOPOSTOP Trials - OncoDaily oncodaily.com/oncolibrary/as…
What were the results of the Postoperative Radiation Therapy in Endometrial Carcinoma (PORTEC) 3 trial? droracle.ai/articles/107827/…
Edu Hortelano retweeted
🚨 The 2024 FROGG Guidelines for Post-Prostatectomy Radiation Therapy (PPRT) are here, bringing groundbreaking updates backed the by the latest evidence❗️@OncoAlert 🧵1/7
Edu Hortelano retweeted
SRS 10+ brain mets week 1/4
Are survival outcomes similar to patients w/2-9 brain mets?
YES, according to this study doi.org/10.3171/2014.8.GKS14…
Ten Practice Changes That I Will Make After Attending ASCO 2024 | PracticeUpdate practiceupdate.com/content/t…
Edu Hortelano retweeted
Replying to @ASTRO_org
@ASTRO_org Updates Rectal Cancer Radiation Therapy Clinical Guideline
🔗 bit.ly/4iIB24X
“This updated guideline incorporates new, practice-changing data that expand treatment options for people with rectal cancer."
#RadOncNews #RadOnc #ASTRO
Edu Hortelano retweeted
🌟 Looking ahead: Prostate Cancer (PCa) management in 2025
Moderator: Amit Bahl | Nuclear Medicine Insights by @karolien_goffin
#PROSCA24 @OncoAlert @mirrorsmed
🔹 PSMA-based Radioligand Therapy (RLT)
🧬 PSMAfore: 12.0 vs 5.6 months (PFS benefit)
🧬 SPLASH: 9.5 vs 6.0 months (PFS benefit)
🧬 ECLIPSE: Promising outcomes! 🌟
🔹 Future of RLT
📡 Integrates isotopes, PET imaging, & immunotherapy
🧪 Exploring alpha therapy: Actinium-225 shows remarkable efficacy!
🔹 Innovative Trials in 2025
🌍 Expanding RLT applications globally
🛠️ Enhancing targeted treatments with PSMA-based approaches
🔹 Beyond Beta
🅱️ Lu-PSMA achieves great outcomes
🔬 Alpha therapies (Actinium-225) show groundbreaking potential 💪
🔹 Radiation Oncology Evolution
🌟 From clinical trials to future standards
🌐 Revolutionizing Nuclear Medicine & PCa Treatment!
@UrsulaVogl
@PGrivasMDPhD
@achoud72
@ZilliThomas
@fabioturco92
@yekeduz_emre
@niklas_kluemper
@nachoduranm
@schmidingerRCC
@DrDabestani
@bavilima
@PignotG
@lisapic
@DrYukselUrun
@b_szabados
@Silke_Gillessen
@APCCC_Lugano
#PSMA #NuclearMedicine #ProstateCancer #PrecisionOncology #RadioligandTherapy #PROSCA24 💡
Edu Hortelano retweeted
A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24
LINK TO ARTICLE👇👇👇👇👇👇👇👇
sciencedirect.com/science/ar…
NOW ON FINAL SESSION of #PROSCA24
The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking.
The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting.
The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer.
Our Thanks to all authors:
@Silke_Gillessen
@fabioturco92
@Prof_IanD
@drjefstathiou
Karim Fizazi
@Prof_Nick_James
Neal Shore
Eric Small
Matthew Smith
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
Emmanuel S. Antonarakis
Ana Aparicio
Andrew J. Armstrong
Diogo Assed Bastos
Gerhardt Attard
Karol Axcrona
Mouna Ayadi
Himisha Beltran
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
Muhammad Bulbul
Consuelo Buttigliero
Orazio Caffo
@cdanicas
@Ecastromarcos
Heather H. Cheng
Kim N. Chi
Caroline S. Clarke
Noel Clarke
Johann S. de Bono
@mdesantis234
@nachoduranm
@EfstathiouEleni
Onyeanunam N. Ekeke
Tamer I.H. El Nahas
@drlouiseemmett
@stefanofanti4
Omolara A. Fatiregun
Felix Y. Feng
Peter C.C. Fong
@fontev1
@Nicola_Fossati
Daniel J. George
@marty_gleave
Gwenaelle Gravis
Susan Halabi
Daniel Heinrich
@ProfKHerrmann
@DrMHofman
Thomas A. Hope
Lisa G. Horvath
Maha H.A. Hussain
@BarbaraJereczek
Robert J. Jones
Anthony M. Joshua
@ravikanesvaran
Daniel Keizman
@FacsRaja
Gero Kramer
@LoebStacy
Brandon A. Mahal
Fernando C. Maluf 75 76,
@quimmateo
David Matheson 78,
Mika P. Matikainen 79,
Ray McDermott 80,
@DrRanaMcKay
Niven Mehra 82,
@amerseburger
@CaPsurvivorship
Michael J. Morris 85,
Hind Mrabti 86,
Deborah Mukherji
@declangmurphy
Vedang Murthy
Shingai B.A. Mutambirwa
@DrPaulNguyen
@WilliamOhMD
@piet_ost
Joe M. O’Sullivan
Anwar R. Padhani
Chris Parker
Darren M.C. Poon
Colin C. Pritchard
Danny M Rabah
Dana Rathkopf
Robert E. Reiter
Raphaele Renard-Penna
Charles J. Ryan
Fred Saad
Juan Pablo Sade
Shahneen Sandhu
Oliver A. Sartor
Edward Schaeffer
Howard I. Scher
Nima Sharifi
Iwona A. Skoneczna
Howard R. Soule
@DrSpratticus
Sandy Srinivas
@cnsternberg
Hiroyoshi Suzuki
Mary-Ellen Taplin
Camilla Thellenberg-Karlsson
Derya Tilki
Levent N. Türkeri
Hiroji Uemura
@DrYukselUrun
Claire L. Vale
Neha Vapiwala
Jochen Walz
Kosj Yamoah
Dingwei Ye
Evan Y. Yu
Almudena Zapatero
@AOmlin
Edu Hortelano retweeted
Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment, published in @TheLancet.
👉 Read it before your patients: bit.ly/3Tr8WzY
#ESTRONewsletter #breastcancer
Edu Hortelano retweeted
🌍 ESTRO at ASTRO! ESTRO President Matthias Guckenberger @Mat_Guc is presenting highlights from the best science of #ESTRO24 at the "Cancer Breakthroughs" session at #ASTRO24. 🚀✨
#CancerResearch #GlobalCollaboration
Edu Hortelano retweeted
Doublet chemotherapy, triplet chemotherapy, or doublet chemoT combined with RT as neoadjuvant treatment for locally advanced #oesophagealcancer: a randomised, controlled, open-label, phase 3 trial, published in @TheLancet.
👉 Read it before your patients: bit.ly/3XRD8WD
Edu Hortelano retweeted
Randomised, double-blind, phase 3 clinical trial for newly diagnosed, high-risk, locally advanced cervical cancer, published in @TheLancet.
👉 Read it before your patients: bit.ly/46Ywx0s
#ESTRONewsletter
Edu Hortelano retweeted
Probably the best current review on PSMA expression ... congrats to @mishabeltran @mkbakht
nature.com/articles/s41585-0…
Check out our new review in @NatRevUrol on biologic determinants of PSMA expression, regulation, and heterogeneity in prostate cancer led by @mkbakht @DanaFarber_GU @PCF_Science
Link to paper: rdcu.be/dM7GF
nature.com/articles/s41585-0…






































